Stockscreener 앱 받기
12.95
0.62%
0.08
시간 외 거래:
12.99
0.04
+0.31%
전일 마감가:
$12.87
열려 있는:
$12.9
하루 거래량:
963.16K
Relative Volume:
0.56
시가총액:
$4.07B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-19.03
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+3.02%
1개월 성능:
+3.43%
6개월 성능:
+59.29%
1년 성능:
+64.97%
1일 변동 폭
$12.82
$13.01
1주일 범위
$12.51
$13.01
52주 변동 폭
$6.685
$13.01
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.95 | 4.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
126.23 | 55.30B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.65 | 49.22B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.89 | 36.41B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
507.16 | 22.16B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Short Squeeze: Why Amneal Pharmaceuticals Inc stock remains a top recommendation2025 Key Highlights & Community Verified Watchlist Alerts - moha.gov.vn
FDA approves Amneal’s two denosumab biosimilars for US market By Investing.com - Investing.com Nigeria
Amneal stock rises after FDA approves two denosumab biosimilars By Investing.com - Investing.com Australia
Amneal Reports FDA Approval of Denosumab Biosimilars - marketscreener.com
Amneal stock rises after FDA approves two denosumab biosimilars - Investing.com
FDA approves Amneal’s two denosumab biosimilars for US market - Investing.com
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - The Manila Times
FDA OKs new biosimilar bone drugs for cancer and osteoporosis - Stock Titan
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection - Sahm
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Market Leaders: What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Momentum & High Return Stock Watch Alerts - Улправда
What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
Operating cash flow per share of Amneal Pharmaceuticals, Inc. Class A – DUS:2DT - TradingView — Track All Markets
New Highs: Is Amneal Pharmaceuticals Inc. stock overvalued by current metrics2025 Risk Factors & High Accuracy Swing Trade Signals - Улправда
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsJuly 2025 Selloffs & Accurate Intraday Trading Signals - DonanımHaber
Will Amneal Pharmaceuticals Inc. stock recover faster than peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - DonanımHaber
Can Amneal Pharmaceuticals Inc. stock continue upward trendProduct Launch & Low Risk Entry Point Tips - DonanımHaber
Aug Patterns: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com South Africa
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockMarket Volume Report & Daily Risk Controlled Trade Plans - Улправда
Why Amneal Pharmaceuticals Inc. stock attracts global investorsMarket Risk Analysis & Real-Time Price Movement Reports - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Decliners & Free High Accuracy Swing Entry Alerts - Улправда
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
Yakima Topic AMNEAL PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KIMA
Squarepoint Ops LLC Buys 420,398 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Institutional Investors Have a Lot Riding on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) With 48% Ownership - news.futunn.com
Esomeprazole Market Set to Witness Significant Growth - openPR.com
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Increased by BlackBarn Capital Partners LP - MarketBeat
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated at Barclays - MarketBeat
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care - Investing.com
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewswire
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
13.98%
0.98%
자본화:
|
볼륨(24시간):